Protease triggered release of molecules from hydrogels
The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme.
1. A composition comprising:
biocompatible hydrogel, comprising a plurality of cross-linkers connecting backbone components of said hydrogel; wherein said hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by a matrix metalloprotease; said inhibitor being effective as a treatment of a condition related to the presence of said matrix metalloprotease; wherein said hydrogel contains binding groups to said inhibitor of matrix metalloprotease to retain the inhibitor within the intact hydrogel; and
a therapeutic agent comprising an inhibitor of matrix metalloprotease encapsulated within said hydrogel.
2. The composition of claim 1 , wherein said hydrogel comprises one or more of hyaluronic acid and polyethylene glycols.
3. The composition of claim 1 , wherein said peptide sequence is incorporated into the cross-linker via reaction of thiol groups of cysteins with acrylates or methacrylates.
4. The composition of claim 1 , where said tissue inhibitor of matrix metalloprotease is TIMP-3.
5. The composition of claim 1 , wherein said matrix metalloprotease is MMP-13 or MMP-2.
6. The composition of claim 1 , wherein said cross-linker comprises said peptide sequence and at least one of hyaluronic acid or polyethylene glycol.
7. The composition of claim 1 , wherein said hydrogels comprise hyaluronic acid.
8. The composition of claim 1 , wherein the hydrogel composition is such that encapsulated inhibitors are released from the hydrogel and into the extracellular matrix of tissue in the presence of pathological levels of matrix metalloprotease.
9. The composition of claim 1 , wherein said peptide comprises a sequence GCRDGPQGIWGQDRCG, GGPQGIWGQGCG, or GCGQGWIGQPGGG.
10. The composition of claim 1 , wherein the inhibitor of matrix metalloprotease is useful in the treatment of myocardial infarction.
11. The composition of claim 1 , wherein inhibitor of matrix metalloprotease reduces left ventricular remodeling associated with myocardial infarction in a patient.
12. The composition of claim 1 , wherein said binding groups attenuate diffusion of encapsulated inhibitors from the hydrogel.